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Psychotic symptoms are a common and debilitating feature of Alzheimer's disease (AD) and are asso-
ciated with a more rapid course of decline. Current evidence from postmortem and neuroimaging studies
implicates frontal, temporal, and parietal lobes, with reported disruptions in monoaminergic pathways.
However, the molecular mechanisms underlying this remain unclear. In the present study, we investi-
gated methylomic variation associated with AD psychosis in 3 key brain regions implicated in the eti-
ology of psychosis (prefrontal cortex, entorhinal cortex, and superior temporal gyrus) in postmortem
brain samples from 29 AD donors with psychosis and 18 matched AD donors without psychosis. We
identified psychosis-associated methylomic changes in a number of loci, with these genes being enriched
in known schizophrenia-associated genetic and epigenetic variants. One of these known loci resided in
the AS3MT genedpreviously implicated in schizophrenia in a large GWAS meta-analysis. We used
bisulfite-pyrosequencing to confirm hypomethylation across 4 neighboring CpG sites in the ASM3T gene.
Finally, our regional analysis nominated multiple CpG sites in TBX15 and WT1, which are genes that have
been previously implicated in AD. Thus one potential implication from our study is whether psychosis-
associated variation drives reported associations in AD case-control studies.
 2020 Published by Elsevier Inc.1. Introduction
Around 40% of peoplewith Alzheimer's disease (AD)will at some
point experience psychotic symptoms, which are distressing, have a
major negative impact on disease course and accelerate the need for
nursing home care (Connors et al., 2018) and for which there are no
effective licensed treatments (Creese et al., 2018). The limited
knowledge of disease mechanisms underlying psychosis in AD
(AD þ P) represents a major obstacle in the identification of novel
treatment targets and understanding the syndrome at a clinical
level. Neuropathological studies implicate increased pTau and TDP-
43 pathology in the pathogenesis of ADþ P (Murray et al., 2014). Theical School, Royal Devon and
ter, EX2 5DW. UK. Tel.: 01392
).
Elsevier Inc.heritability of ADþ P is estimated to be 61% (Bacanu et al., 2005) and
linkage studies (Hollingworth et al., 2007) and population level
analyses of common single-nucleotide polymorphisms and copy
number variants provide further support for a genetic basis to the
syndrome (Barral et al., 2015; Hollingworth et al., 2007; Zheng et al.,
2015). Interestingly, some of these studies suggest genetic linkswith
schizophrenia (SZ) (Creese et al., 2019; DeMichele-Sweet et al.,
2018), thus raising the question as to whether there are common
mechanisms that underpin psychosis across the life span. These
genomic and neuropathological studies provide compelling evi-
dence that AD þ P represent a syndrome of AD with a distinct
neurobiological profile, potentially offering exciting opportunities
for precision medicine. However, neuropathology explains only
~18%ofADþPvariance (Krivinko et al., 2018),whereas the genomics
of other complex disorders suggest that common single-nucleotide
polymorphisms alone are likely to only explain a small proportion of
variance (Golan et al., 2014). Therefore, further research is required
to provide a better understanding of the molecular mechanisms
E. Pishva et al. / Neurobiology of Aging 89 (2020) 83e8884underlying AD þ P, and whether this presents novel precision
treatment opportunities.
In recent years, epigenome-wide association studies (EWAS)
have transformed our understanding of the molecular etiology of
AD (Lunnon et al., 2014; Smith et al., 2019, 2018) and psychiatric
conditions, including SZ (Viana et al., 2017). Here, we present the
first EWAS of AD þ P in cortical samples from pathologically
confirmed AD cases that had undergone a standardized assessment
of psychotic symptoms during life, hypothesizing that alterations in
DNA methylation are associated with AD þ P.
2. Materials and methods
2.1. Sample selection
This study used DNA methylomic data previously generated by
our group using postmortem human brain tissue from the MRC
London Neurodegenerative Disease Brain Bank using the Illumina
Infinium HumanMethylation450 K BeadChip (Lunnon et al., 2014)
(GEO accession number GSE59685). Data from a total of 141
matched cortical samples from the entorhinal cortex (EC), prefrontal
cortex (PFC), and superior temporal gyrus (STG) were used from 29
AD þ P subjects and 18 AD subjects without psychosis (AD-P)
(Supplementary Table 1). Samples and clinical datawere collected as
part of theAlzheimer's ResearchUK funded study “Biomarkers of AD
Neurodegeneration”; participants were recruited through second-
arycare in Englandwith informed consent provided according to the
Declaration of Helsinki (World Medical Association, 1991). During
life, all cases received a clinical diagnosis of dementia. At postmor-
tem, all cases underwent a thorough standardized examination and
all cases in the present analysis were diagnosed with AD postmor-
tem. There was no significant difference in the distribution of
neurofibrillary tangle Braak stage between the AD-P and AD þ P
groups. The following comorbid pathologies were present in the
cohort but numbers (provided in Supplementary Table 1) were not
significantly different across AD þ P and AD-P groups: TDP-43, ce-
rebral amyloid angiopathy (CAA), vascular pathology (including
small vessel disease), Lewy body pathology (brain stem or limbic
predominant). Therewere no cases with cortical Lewy body disease.
Psychosis was assessed using the Neuropsychiatric Inventory (NPI),
a ten-item scale measuring a range of neuropsychiatric symptoms
reported in dementia (Cummings et al., 1994). Assessment with NPI
was undertaken at baseline and average Mini-Mental State Exami-
nation at the time of assessment was 12.7 (SD¼ 9). For this analysis,
symptoms were coded as present (>0 on either the delusion or
hallucination items of the NPI) or absent (no symptoms).
2.2. Illumina 450K array data analysis
The raw signal intensities for the arrays were imported into R
(version 3.6). Stringent quality control and normalization were
performed separately for each region using wateRmelon and
methylumi packages in R as described previously (Lunnon et al.,
2014). The minfi package in R was used to estimate the propor-
tion of neuronal cells across samples for each tissue (Aryee et al.,
2014). The effects of age, sex, and derived neuronal cell propor-
tion were regressed out from the normalized methylation beta
values for all samples before subsequent analysis. Principal
component analysis demonstrated that variables such as post-
mortem interval and batch did not impact on the data and so these
were not included as covariates. Global analysis of DNAmethylation
data were estimated by the cumulative distribution function of the
methylation values for each individual using B-spline basis func-
tions using the GAMP package in R (v.0.11) (Zhao et al., 2015). The
estimated global DNA methylation levels in the AD þ P and AD-Pgroups were compared in each of the cortical brain regions. To
identify differentially methylated positions (DMPs) consistently
associated with ADþ P across all 3 cortical regions, we performed a
linear model analysis using generalized least squares (‘gls’ function
in nlme R package [Pinheiro et al., 2019]), which allows for a fully
unstructured variance-covariance matrix of the residuals. Fixed
effects were specified in such a way that we directly obtained the
pooled estimate and standard error across the brain regions.
Quantile-quantile (Q-Q) plots were used to assess the inflation in-
dex (Supplementary Fig 1). DMPs were ranked by both p-value and
the magnitude of effect size. To identify differentially methylated
regions (DMRs), we used the Python module comb-p to group 3
spatially correlated p-values in a 500-bp sliding window (Pedersen
et al., 2012). To test for an enrichment of the AD þ P EWAS loci in
known SZ GWAS variants we used Fisher's method to combine
together AD þ P EWAS p-values for probes residing in the inde-
pendent genomewide significantly associated regions nominated in
the most recent SZ GWAS meta-analysis (Pardinas et al., 2018). Of
the 145 regions identified by Pardinas et al, 101 contained >1 CpG
site on the 450K array and were used in our analyses. Finally, to test
for an enrichment of the AD þ P EWAS loci in known SZ EWAS
variants, we used a one-sided Fisher's test to test whether the 1000
top-ranked ADþ P-associated probes in our EWASwere enriched in
a list of 1894 significant SZ-associated probes (PFDR < 0.05) from a
recent SZ EWAS of PFC (Jaffe et al., 2016).
2.3. Targeted validation using bisulfite pyrosequencing
Bisulfite pyrosequencing was used to replicate DNA methylation
in the same samples and tissues across 6 individual CpG sites in the
AS3MTgene, spanning from chr10:104,629,829-104,629,929 (hg19).
Bisulfite conversion was performed using the EZ DNA Methylation-
Gold kit (Zymo Research, USA). A single amplicon (101 bp) was
generated using primers designed using the PyroMark Assay Design
software 2.0 (Qiagen, UK). Pyrosequencing was performed using 2
sequencing primers to maximize coverage across the 5 CpG sites.
DNA methylation was quantified using the Pyromark Q24 system
(Qiagen, UK) using the manufacturer's standard instructions and
the Pyro Q24 CpG 2.0.6 software. To examine the combined effect of
the CpGs across the designed amplicon for pyrosequencing, the
measured DNA methylation for each site was tested using the
generalized least square method and estimates and corresponding
variance-covariance matrix of the estimates were subjected to the
“rma” function in the metafor R package (v2.1) (Viechtbauer, 2010).
3. Results and discussion
3.1. AD þ P is characterized by common patterns of methylation
across brain regions
The aim of this study was to identify distinct patterns of DNA
methylation associated with the presence of psychosis in AD.
Therefore, we performed an EWAS in the 29 AD þ P and 18 AD-P
samples, while controlling for confounders such as age, sex, and
derived neuronal cell proportions. First, we used the cumulative
distribution function of the methylation values for each individual
to quantify global methylation levels across samples and observed
no difference in global DNA methylation between AD þ P and AD-P
individuals in any of the 3 brain regions examined (PFC: p ¼ 0.99,
EC: p ¼ 0.52, STG: p ¼ 0.76). Next, we examined DNA methylation
differences between AD þ P and AD-P subjects at individual loci
covered by the array, with the 1000 top-ranked loci (based on both
effect size and p value) shown in Supplementary Table 2. Although
no CpGs survived the stringent Bonferroni significance threshold of
p < 1.66E-07, a number of loci showed similar patterns of
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probe (cg19596870, estimate¼0.173, p¼ 3.42E-04) and the 11th-
ranked probe (cg01266060, estimate ¼ 0.029, p ¼ 3.00E-05)
reside within the SERPINB6 gene, located 498 bp downstream from
the TSS and in the gene body, respectively. This gene is expressed in
the brain and has been previously identified in an SZ-coagulation
gene interaction network (Huang et al., 2014). We also identified
DMPs annotated to other genes that have previously been impli-
cated in SZ; our 76th ranked loci resided within the body of the
AS3MT gene (cg08772003, estimate¼0.025, p¼ 7.50E-04), where
increased gene expression has been linked to SZ risk alleles in the
10q24.32 SZ-related locus.3.2. A number of DMRs spanning multiple adjacent CpGs are seen in
AD þ P
We identified 2 DMRs, each with consistent hypomethylation in
the AD þ P group in all 3 cortical regions (Supplementary Table 3).
These regions corresponded to 10 CpG sites (613 bp) within the first
exon of the TBX15 gene (Fig. 1A: PSidak ¼ 5.88E-09) and 8 CpG sites
(476bp) in thefirst intronof theWT1gene (Fig.1B: PSidak¼3.00E-08).3.3. Differentially methylated loci in AD þ P are enriched for known
SZ variants
Given that several of our top-ranked DMPs appeared to have
been previously associated with SZ, we were interested whether
there was a significant enrichment of significant DMPs within
known SZ-associated variants. To this end, using themost recent list
of independent SZ-associated genomic regions from Pardinas et al.,
(2018), we examined the enrichment of AD þ P-associated DMPs
residing in the linkage disequilibriumblocks harboring risk variants.
101 of the 145 linkage disequilibrium blocks contained >1 CpG site
on the 450K array and using Fisher's methodwe combined p-values
within each of these blocks, identifying a significant enrichment in
our data in locus 1 after correcting for multiple testing (Chr6:
24,988,105-33,842,877; xMHC (10,409 probes), PFDR ¼ 1.21E-04)Fig. 1. Two DMRs consisting of multiple adjacent DMPs can be identified in AD þ P. (A)
methylation in AD þ P (red) compared with AD-P (orange) in all 3 cortical brain regions.
methylation level (%). Abbreviations: AD, Alzheimer's disease; AD þ P, psychosis in AD; DM
figure legend, the reader is referred to the Web version of this article.)(Supplementary Table 4). Notably, we observed that 40 of the genes
annotated to our 1000 top ranked AD þ P probes were in the sig-
nificant SZ EWAS probe list with the same direction of effect,
including TBX15. When we correlated the t-statistics of our EWAS
with the SZ EWAS for these 40 CpG sites we observed a highly sig-
nificant correlation (r¼ 0.87, p¼ 2.672E-13). Finally, we found 19 of
the genes we identified in our ADþ P EWAS were present in the list
of 376 differentially expressed genes (at FDR) in the recent meta-
analysis of transcriptomic data in SZ by Manchia et al., (2017),
demonstrating a significant enrichment (p ¼ 0.035).3.4. Bisulfite pyrosequencing replicates hypomethylation of the
AS3MT gene in cortex
We used bisulfite pyrosequencing to quantify DNA methylation
across an extended region of 101 bp spanning 5 CpG sites, including
cg08772003, one of the top-ranked DMPs we had identified within
the exonic region of AS3MT. This gene was selected for validation
given its reported role in the pathogenesis of SZ (Li et al., 2016). In
our 450K analysis, we had observed hypomethylation in AD þ P at
cg08772003 in all 3 cortical regions (Fig. 2A). Using pyrosequenc-
ing, we observed a trend toward significant hypomethylation across
the 3 regions (Fig. 2B), with DNA methylation values calculated on
the 450K array being highly correlatedwith the values calculated by
pyrosequencing (Fig. 2C). Our pyrosequencing assay covered 4
additional CpG sites, 3 of which were downstream of cg08772003
(Supplementary Table 5). Interestingly, these 3 CpGs all showed the
same direction of effect as the CpG covered by the 450K probe
(hypomethylation) (Fig. 2DeE), and whenwe averagedmethylation
across the 4 hypomethylated sites, these showed significant hypo-
methylation (p ¼ 0.0011) associated with AD þ P.4. Conclusions
We examined cross-cortical DNA methylation changes associ-
ated with AD þ P in a series of clinically and neuropsychological
well-characterized cases. We found consistent patterns of DNATen DMPs showed hypomethylation in TBX15 and (B) 8 DMPs in WT1 showed hypo-
Shown on the X axis is genomic location. Shown on the Y axis is the corrected DNA
R, differentially methylated region. (For interpretation of the references to color in this
Fig. 2. AS3MT shows consistent hypomethylation in AD þ P using 2 different technologies. In the 450K array data, we demonstrated significant AD þ P-associated hypomethylation
across all 3 cortical brain regions at cg08772003 (A), with a similar trend at this loci when replicated using pyrosequencing (B) and a significant correlation of methylation levels
calculated by the 2 technologies (C). Three neighboring downstream CpG sites covered by the pyrosequencing assay also showed psychosis-associated hypomethylation across the
cortex, which was significant across the region (D, E). Abbreviations: AD, Alzheimer's disease; AD þ P, psychosis in AD; DMR, differentially methylated region.
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the top-ranked loci being enriched for known EWAS and GWAS SZ
loci. To our knowledge, this is the first evidence implicating DNA
methylation in AD þ P and adds further support for transdiagnostic
hypotheses linking psychotic disorders across the life span.
We identified DMRs in TBX15 and WT1, which were hypo-
methylated in AD þ P relative to AD-P. It is interesting to note that
these genes have been previously reported in the context of AD;
TBX15 has been shown to be hypomethylated in the STG of AD cases
relatives to non-AD controls (Watson et al., 2016), while WT1 has
been previously shown to be present in neurofibrillary tangles
(Lovell et al., 2003). Although our findings should be replicated in
independent cohorts, one potential important broader implication
from our study is whether AD þ P-associated variation drives re-
ported genetic, epigenetic, or transcriptomic associations previ-
ously identified between AD cases and non-AD controls. Given that
around ~40% of patients with AD will experience psychosis
(Connors et al., 2018), which is seldom measured or reported, it is
plausible that psychosis could represent a significant confounder in
AD case-control studies, which cannot easily be accounted for.There are several converging lines of evidence to suggest that
psychotic symptoms across the life span have some common
mechanisms. Recent genomic research has linked polygenic risk for
SZ to psychotic symptoms in Huntington's disease (Ellis et al., 2019)
and AD (Creese et al., 2019), as well as psychotic experiences in the
general population (Legge et al., 2019), while neuropsychological
testing implicates similar deficits in processing speed and executive
function in individuals with very-late-onset SZ-like psychosis and
ADþ P (Van Assche et al., 2019). Our findings that top-ranked ADþ
P-associated DMPs are enriched for SZ loci extend this evidence
base into molecular-level mechanistic similarities for the first time.
We are unable at present to determine whether the AD þ P-
associated DNA methylation patterns we have identified are causal
or a consequence of the psychotic episodes. Nonetheless, given that
many of the top ranked loci overlapped with known psychosis-
associated genetic variants, it does suggest that some of the
epigenetic variation we have identified may lie upstream of
symptom onset. There are a number of other limitations to our
study, for example the use of bulk tissue, which contains both glia
and neuronal cell types and our relatively small sample size in this
E. Pishva et al. / Neurobiology of Aging 89 (2020) 83e88 87study. Although we were able to validate AD þ P-associated
hypomethylation in the AS3MT gene using another technology, this
was on the same samples and thus it will be important in the future
to validate our findings in additional similarly well-characterized
cohorts. Nonetheless, the quality of clinical and neuropathological
phenotyping is a key strength of our study and our findings provide
a clear rationale for further molecular level profiling of AD þ P.
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